Johannes H.A.M. Kaanders PhD , Johan Bussink PhD , Erik H.J.G. Aarntzen PhD , Pètra Braam PhD , Heidi Rütten MD , Richard W.M. van der Maazen PhD , Marcel Verheij PhD , Sven van den Bosch PhD
{"title":"[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription","authors":"Johannes H.A.M. Kaanders PhD , Johan Bussink PhD , Erik H.J.G. Aarntzen PhD , Pètra Braam PhD , Heidi Rütten MD , Richard W.M. van der Maazen PhD , Marcel Verheij PhD , Sven van den Bosch PhD","doi":"10.1016/j.semradonc.2023.03.006","DOIUrl":null,"url":null,"abstract":"<div><p>PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.</p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429623000206","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.
期刊介绍：
Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
